Vnitr Lek 2017, 63(10):667-671 | DOI: 10.36290/vnl.2017.130

COSYREL - an efficient fixed combination for treatment of hypertension, stable ISHD and heart failure

Jiří Widimský
III. interní klinika 1. LF UK a VFN v Praze

Fixed combinations of two or three drugs are being frequently used in cardiovascular diseases. This approach markedly increases adherence of the patients to prolonged therapy and thus leads to better control of the diseases. Fixed combinations are often used in hypertension and coronary artery disease (CAD). Cosyrel is the first fixed combination of betablocker (bisoprolol fumarat) and ACE inhibitor (perindopril arginin) available in czech market. The advantage is availability in several concentrations (10 mg/10 mg, 10 mg/5 mg a 5 mg/10 mg a 5 mg/5 mg) , when first indicates bisoprolol dose and the second perindopril. This combination is indicated in arterial hypertension and/or in stable CAD (in patients after myocardial infarction or revascularisation) and/or in dosages 5 mg/5 mg and 5 mg/10 mg in patients with chronic heart failure with systolic dysfunction. This article aimed to evaluate briefly clinical characteristics of this fixed combination. Bisoprol and perindopril arginin have a lot of data indication their positive impact on CV risk and prognosis.

Keywords: bisoprolol; coronary artery disease; heart failure; hypertension; perindopril

Received: August 25, 2017; Accepted: September 22, 2017; Published: October 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. COSYREL - an efficient fixed combination for treatment of hypertension, stable ISHD and heart failure. Vnitr Lek. 2017;63(10):667-671. doi: 10.36290/vnl.2017.130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55(2): 399-407. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.139816>. Go to original source... Go to PubMed...
    2. Hess G, Hill J, Lau H et al. Medication utilization patterns and hypertension-related expenditures among patiens who were switched from fixed-dose to free-combination antihypertensive therapy. PT 2008; 33(11): 652-666.
    3. Filipovský J, Widimský J Jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785-801. Go to PubMed...
    4. Corrao G, Nicotra F, Parodi A et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drug in daily life practice. Hypertension 2011; 58(4): 566-572. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.177592>. Go to original source... Go to PubMed...
    5. Gradman AH, Parisé H, Lefebvre P et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61(2): 309-318. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.201566>. Go to original source... Go to PubMed...
    6. Bussien JP, d'Amore TF, Perret L et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther 1986; 39(5): 554-558. Go to original source... Go to PubMed...
    7. Hui Y, Dai Z, Chen X et al. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. Chin Med J Engl 1995; 108(9): 678-681. Go to PubMed...
    8. Taddei S. Bortolotto L. Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity. Am J Cardiovasc Drugs 2016; 16(5): 309-321. Dostupné z DOI: <http://dx.doi.org/10.1007/s40256-016-0173-4>. Go to original source... Go to PubMed...
    9. Van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33(16): 2088-2097. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs075>. Go to original source... Go to PubMed...
    10. Cosyrel. Souhrn údajů o přípravku. SUKL 2016. Dostupné z WWW: <http://www.sukl.cz/modules/medication/detail.php?code=0209912&tab=texts>.
    11. Vítovec J, Špinar J. Diuretika a betablokátory v léčbě hypertenze. Interní Med 2012; 14(12): 458-460.
    12. Vítovec J, Špinar J. Betapres - nová fixní kombinace pro preventivní kardiologii. Hypertenze a kardiovaskulární prevence 2014; 3(1): 30-32.
    13. Poulter NR, Wedel H, Dahlöf B et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366(9489): 907-913. Go to original source... Go to PubMed...
    14. The European trial On reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782-788.
    15. Yusuf S, Sleight P, Pogue J et al. [Heart Outcomes Prevention Evaluation Study Investigators]. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342(3): 145-153. Erratum in 2000; 342(18): 1376. N Engl J Med 2000; 342(10):748. Go to original source... Go to PubMed...
    16. Bertrand ME, Ferrari R, Remme WJ et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J 2015; 170(6): 1092-1098. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2015.08.018>. Go to original source... Go to PubMed...
    17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353(9146): 9-13. Go to original source...
    18. Widimský J Jr, Widimský J et al. Hypertenze. 4. vyd. Triton: Praha 2014. ISBN 978-80-7387-811-5.
    19. Widimský J, Widimský J Jr. Farmakoterapie hypertenze. Maxdorf: Praha 2016. ISBN 978-80-7345-477-7.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.